media – Page 210 – DrugDu- Global Leading Pharmaceutical & Medical Device Platform

Study reveals AI can predict patients’ survival in glioblastoma

The aggressive brain cancer is responsible for over 3,000 cases in the UK every year Researchers from King’s College London (KCL) have developed an artificial intelligence (AI)-based model that can predict adult brain cancer patients’ rates of survival after receiving radiotherapy treatment. Published in Neuro-Oncology, researchers applied deep learning to predict whether glioblastoma patients would survive eight months. Responsible for around 3,200 cases every year in the UK, glioblastoma is a very aggressive and difficult-to-treat cancer, with just one in four patients surviving over one year after diagnosis. Currently, patients are regularly and routinely tested to see whether chemotherapy is effective or not. However, some patients can suffer from harmful side effects as a result of chemotherapy. Instead, by giving patients an instantaneous and accurate prediction from a single routine MRI scan, the AI will allow doctors to identify patients who would not benefit from chemotherapy and try a different ...
- Source: https://pharmat.com/news/study-reveals-ai-can-predict-patients-survival-in-glioblastoma/
- 114
- February 12, 2024
Study reveals SARS-CoV-2 can infect dopamine neurons causing senescence

Dopamine neuron senescence is a hallmark of Parkinson’s disease Weill Cornell Medicine, Memorial Sloan Kettering Cancer Center and Columbia University Vagelos College of Physicians and Surgeons have reported that SARS-CoV-2 can infect dopamine neurones in the brain, triggering senescence. Long COVID patients should be monitored for an increased risk of developing Parkinson’s disease (PD)-related symptoms, as dopamine neuron senescence is a hallmark of the condition. The study revealed that dopamine neurons that are infected with SARS-CoV-2, the virus that causes COVID-19, stop working and send out chemical signals that cause inflammation, triggering senescence, when a cell loses the ability to grow and divide. Neurons produce dopamine, a neurotransmitter that acts on areas of the brain and causes feelings of pleasure, motivation, memory, sleep and movement. Damage to these neurons is also associated with PD, a neurodegenerative disorder that progressively damages parts of the brain. After generating multiple cell types from ...
- Source: https://news.weill.cornell.edu/news/2024/01/sars-cov-2-can-infect-dopamine-neurons-causing-senescence
- 178
- February 12, 2024
New programme shown to help dementia patients live independently

The neurodegenerative condition currently affects over 944,000 people in the UK A new programme led by Queen Mary University of London and funded by the Alzheimer’s Society has received positive trial results that could benefit carers and patients living with dementia. The New Interventions for Independence in Dementia (NIDUS-Family) programme was successful in supporting patients and carers to achieve their goals compared to those who received usual care. Affecting more than 944,000 people in the UK, dementia is a neurodegenerative disease that impairs a person’s ability to remember, think or make decisions on a daily basis. Set up at University College London and now running at Queen Mary’s University London, NIDUS-Family aims to understand how to support carers who look after those with dementia at home. Researchers tested the programme on a small number of participant pairs with over 300 people living with dementia and their unpaid carers. The first ...
- Source: https://pharmatimes.com/news/new-programme-shown-to-help-dementia-patients-live-independently/
- 98
- February 11, 2024
Regeneron’s linvoseltamab application accepted for review

Regeneron Pharmaceuticals marketing authorisation application (MAA) for linvoseltamab has received acceptance for review from the European Medicines Agency (EMA) to treat adults with r/r MM. Linvoseltamab is a bispecific antibody designed to target and destroy cancer cells by bridging the B cell maturation antigen on MM cells with CD3 (cluster of differentiation 3, a protein complex)-expressing T cells. The MAA submission is based on findings from the Phase I/II LINKER-MM1 clinical trial of linvoseltamab in r/r MM patients. The open-label, multicentre, dose-escalation and dose-expansion study is designed to evaluate the investigational drug in patients who have undergone multiple prior treatments. All 282 enrolled trial subjects had received a minimum of three lines of therapy or were considered triple refractory. They subsequently received linvoseltamab through an initial step-up dosing regimen, followed by a full dose. The completed Phase I portion of the trial evaluated the tolerability, safety ...
- Source: https://www.echnology.com/news/regeneron-linvoseltamab-application-review/
- 102
- February 11, 2024
Hemogenyx gets reprieve as FDA lifts clinical hold on AML CAR-T therapy

Hemogenyx has received the all-clear from the US Food and Drug Administration (FDA) to begin a Phase I clinical trial of its acute myeloid leukaemia (AML) chimeric antigen receptor (CAR) T-therapy in the US. In June 2023, the US FDA placed a clinical hold on the trial for HEMO-CAR-T, requesting additional information from Hemogenyx after a splicing deficiency during manufacture of the lentivirus used to produce CAR-T cells. Hemogenyx produced a plan, supported by laboratory tests to address FDA’s concerns in August 2023, which was accepted the following month. In January, the London, UK-based biopharma issued a complete response to the agency to lift the hold. Hemogenyx’s stock price has increased by 62% following the announcement of the lifting of the hold today (9 February) since the market close yesterday.CAR-T therapies have been hitting the headlines recently after the FDA launched an investigation into the incidence of potentially associated secondary ...
- Source: drugdu
- 160
- February 10, 2024
Multiplexed PCR Test for Pathogen Detection and Antibiotic Resistance Helps Deliver Rapid UTI Treatment

Individuals suffering from urinary tract infections (UTIs) face the risk of continued pain and discomfort, chronic infections, kidney infections, and in severe cases, sepsis. This makes timely and accurate diagnosis of UTIs crucial. Now, a novel multiplexed PCR test capable of detecting 26 pathogens and 12 antibiotic resistance gene markers can assist clinicians in administering rapid UTI treatment. PathogenDx (Scottsdale, AZ, US) has launched D3 Array-UTI which is based on the company’s patented Dynamic Dimensional Detection (D3 Array) technology. This cutting-edge multiplexed molecular diagnostics technology offers triple-redundant testing for quality assurance and provides both qualitative as well as quantitative results in a single reaction. Additionally, it offers automated, cloud-based data analysis, reporting, and management. PathogenDx’s advanced microarray testing platform is designed for human diagnostics (for research use only), as well as for the food and agricultural industries. It can rapidly detect and identify up to 50 pathogens simultaneously in a ...
- Source: drugdu
- 75
- February 10, 2024
AbbVie’s full year 2023 sees 6.4% net revenue drop

AbbVie has reported a decrease in net revenues to $54.32bn for the year ended 31 December 2023, marking a 6.4% decline from the previous year’s $58.05bn.The company’s diluted earnings per share (EPS) on a generally accepted accounting principles basis also fell sharply by 59% to $2.72, compared to $6.63 in 2022.Adjusted diluted EPS saw a 19.3% decrease from $13.77 to $11.11. The company’s global immunology portfolio, which faced stiff competition from Humira biosimilars, saw revenues decrease by 9.6% to $26.14bn.Humira’s global net revenues stood at $14.40bn while Skyrizi and Rinvoq contributed $7.76bn and $3.97bn respectively. In the oncology sector, AbbVie’s global net revenues experienced a 10.1% decrease, amounting to $5.92bn.Its neuroscience portfolio showed resilience with an 18.2% increase in global net revenues, reaching $7.72bn. The aesthetics portfolio, however, recorded a slight decrease of 0.8%, with revenues of $5.29bn.AbbVie has provided an adjusted diluted EPS guidance range for 2024 between $11.05 ...
- Source: drugdu
- 114
- February 10, 2024
Novo Holdings acquires Catalent for $16.5bn

Novo Holdings, the Novo Nordisk Foundation’s holding and investment company, declared plans for a $16.5bn acquisition of Catalent as the company expands its manufacturing capabilities. In the merger, Novo Holdings will receive all outstanding shares of Catalent for $63.50 per share in cash. This price reflects a premium of 39.1% to the closing price of Catalent’s common stock on 28 August 2023. This date was the contract development and manufacturing organisation’s (CDMO) last trading day before announcing Catalent’s new strategic and operational review committee, which assessed the company’s business strategy and operations. The Catalent board unanimously advised Catalent stockholders to complete the merger. In a 5 February press release, Novo expressed plans to complete the deal towards the end of this year, dependent on closing conditions, which include gaining approval from Catalent’s stockholders and securing necessary regulatory approvals. Novo is flush with cash these days as is evident in Novo ...
- Source: drugdu
- 102
- February 10, 2024
RegenxBio advances two candidates to make waves in the CNS space

US-based biotech RegenxBio is seeing a pivotal Phase III study on the horizon as its Phase I/II AFFINITY study of RGX-202 for Duchenne muscular dystrophy (DMD) completes patient enrolment for the second dose level. In a 7 February press release, the company announced that of the three patients treated with dose level 1 of RGX-202 in the AFFINITY trial (NCT05693142), the third patient demonstrated by far the largest increase (83.4%) in microdystrophin expression compared to control at three months. In DMD, a mutation in the dystrophin gene normally responsible for protecting muscle fibres from progressively breaking down contributes to the condition. Microdystrophin is an abbreviated yet functional version of dystrophin, and its expression is often used as a surrogate measure to evaluate therapies. The patient also showed a decrease (93%) in serum creatinine kinase (CK) levels from baseline at ten weeks. The company expects to initiate a pivotal study for ...
- Source: drugdu
- 131
- February 9, 2024
Reuters

After Novartis reportedly backed out of late-stage talks to acquire Cytokinetics earlier this year, the company appears to still be on the M&A prowl.Novartis is in advanced talks to acquire German cancer drug maker MorphoSys, Reuters reports, citing two people familiar with the matter. The anonymous sources stayed mum on details about the bid and a potential acquisition price, according to the news service. Also involved in the MorphoSys M&A talks is Incyte, according to Reuters.As a “matter of policy,” Novartis does not comment on “market rumors/speculations,” a company spokesperson said over email. Incyte and MorphoSys did not immediately respond to Fierce Pharma’s requests for comment. Both known bidders have preexisting ties to the company, with Novartis taking over a MorphoSys preclinical cancer program in 2022 and Incyte partnering on MorphoSys’ sole commercial product, the lymphoma med Monjuvi.Monjuvi garnered $92 million in U.S. sales last year, and MorphoSys expects 2024 sales of between $80 million and $95 million. The Novartis ...
- Source: drugdu
- 115
- February 9, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.